Why the study?
Does a combined cardiac imaging and plasma biomarker approach improve risk stratification for adverse clinical events in patients with left ventricular non-compaction?
Does a combined cardiac imaging and plasma biomarker approach improve risk stratification for adverse clinical events in patients with left ventricular non-compaction?
A combined approach using cardiac imaging and B-type natriuretic peptide can enhance risk assessment in left ventricular non-compaction, minimizing overdiagnosis while identifying true disease.
Answers are grounded in this paper and cite their sources.
May support combined imaging-biomarker risk stratification in LVNC; leaves open prospective validation before practice change.
=0.041). Conclusions The risk of adverse clinical events is increased in the presence of significant compacted myocardial thinning, an elevated B-type natriuretic peptide or increased left ventricular dimensions. The combination of these markers may enhance risk assessment to minimize left ventricular non-compaction overdiagnosis whilst facilitating appropriate diagnoses in those with true disease.
No takes yet. Share an insight, caveat, or question.
Ramchand et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: